A Novel Medication to Help Quit Smoking
Medical Author: Melissa Conrad Stoppler, MD
Medical Editor: Jay W. Marks, MD
In May 2006, the U.S. Food and Drug Administration (FDA)
approved the medication Chantix (varenicline tartrate) to help cigarette smokers stop smoking
. Chantix received a priority FDA review because of its potential,
important benefit to public health.
Varenicline tartrate is unique in that it mimics the actions of nicotine on
the brain and can help both in easing nicotine withdrawal symptoms and blocking
the reinforcing effects of nicotine if smoking is resumed. Two reports in the
August 14/28, 2006 issue of the Archives of Internal Medicine have demonstrated
the effectiveness of varenicline in both short- and long-term smokers who wish
to quit smoking. The researchers report that treatment with varenicline tartrate
led to response rates three times higher than placebo in smokers aged 18 to 65
who were attempting to quit smoking.
Previously available smoking cessation treatments include nicotine
replacement therapy (gum, nasal spray, patches, and inhalers) and the
antidepressants bupropion hydrochloride (Zyban), and nortriptyline hydrochloride. All of
these treatments have limited efficacy, with success rates ranging from 7 to 30%
in clinical studies. Future studies must be carried out to determine the
effectiveness of varenicline (Chantix) treatment compared with each of these established
smoking cessation therapies.
The recent studies also showed that varenicline (Chantix) was relatively well-tolerated by
the smokers who took part in the study. Nausea was the most common side effect
of the drug, and other side effects included headache, vomiting, flatulence (gas)
, insomnia, abnormal dreams, and changes in taste perception.
The FDA-approved course of treatment with varenicline (Chantix) is twelve weeks. If smoking
cessation is successful during the initial twelve-week treatment, a further
twelve-week treatment may be given to increase the probability of long-term cessation
of smoking.
Varenicline (Chantix) is manufactured and distributed by Pfizer, Inc., New York, NY.
For related information, please read the Quitting Smoking article.
References: Arch Intern Med. 2006;166:1571-1577; Arch Intern Med.
2006;166:1561-1568; FDA approves new drug for smoking cessation, FDA Consumer
magazine, July/August 2006.
Last Editorial Review: 8/15/2006